Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

  • days left to enroll
  • participants needed
  • sponsor
    Sumithira Vasu
Updated on 25 January 2021
stem cell transplantation
myeloid leukemia
white blood cell count
monoclonal antibodies
blast cells
white blood cells
monoclonal protein
donor lymphocyte infusion


This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back after a stem cell transplant. A donor lymphocyte infusion is a type of therapy in which lymphocytes (white blood cells) from the blood of a donor are given to a participant who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Giving daratumumab and donor white blood cells may work better in treating participants with acute myeloid leukemia.



I. To evaluate safety and tolerability of daratumumab and escalating doses of donor lymphocyte infusions (DLI) in post-hematopoietic cell transplantation (HCT) patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) transformed to AML (phase I).

II. To evaluate overall response rate to daratumumab and DLI in patients with post-HCT relapsed AML and MDS (phase II).


I. To assess overall response rates in minimal residual disease (MRD) positive patients and in patients with overt morphological relapse.

II. To assess MRD conversion rates from MRD positive to MRD negative. III. To determine the post-relapse 6-month overall response (OS) rates of patients with relapsed AML and MDS following allogeneic hematopoietic stem cell transplantation (allo-HSCT) who are treated with daratumumab.

IV. To determine the rates of graft-versus-host disease (GVHD) (both grades II-IV and III-IV) and autoimmune side effects of daratumumab.

V. To determine the post-relapse 6-month progression-free survival (PFS) rates of patients with relapsed AML and MDS following allo-HSCT who are treated with daratumumab.


I. To compare CD38 expression levels in myeloid blasts and interferon gamma (IFN-y) levels in plasma at the time of relapse before starting daratumumab and at progression or relapse after daratumumab.

II. To compare peripheral blood T cell number and subsets (CD3, CD4, CD8, (CD38 expression on regulatory T cells [T-regs], CD4 and CD8), T regs, B-regulatory cells, natural killer (NK) cell numbers and bone marrow T cell subsets at the time of relapse before starting daratumumab, at the time of partial/complete response to daratumumab, and at the time of progression or relapse after daratumumab.

III. To evaluate whether daratumumab has (i) direct anti-leukemia effects (ii) antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) and (III) immune modulation of autologous immune system (NK cells, T cells, T-regs, B-regulatory cells [B-regs], and myeloid-derived suppressor cells [MDSCS]) in AML.

IV. To evaluate the effect of daratumumab on exosome content and clearance along with other soluble factors in AML.

V. To evaluate serum interferon (IFN) levels pre-daratumumab, during and post-daratumumab.

VI. To evaluate whether fratricide occurs in patients treated with daratumumab.

OUTLINE: This is a phase I, dose escalation study of donor lymphocyte infusions followed by a phase II study.

Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity. Participants found to be in complete response (CR) at the end of 8 weeks may receive daratumumab IV once every 2 weeks for 8 weeks, and then once monthly for 6 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up for 1 year.

Condition Minimal Residual Disease, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Treatment laboratory biomarker analysis, Daratumumab, Donor Lymphocyte Infusion
Clinical Study IdentifierNCT03537599
SponsorSumithira Vasu
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

AML relapse following Allo-HSCT (Morphological relapse, or MRD positive verified by flow cytometry, cytogenetics, and molecular mutations)
MDS transformed to AML following Allo-HCT
Patients who received a 10/10 HLA-matched allogeneic HCT either from sibling donors or unrelated donors or atleast a 5/10 haploidentical transplant
Engraftment must have occurred as defined by platelet (PLT) count > 20,000/L and ANC
Eastern Cooperative Oncology Group (ECOG) performance status < 3
Creatinine clearance > 40 ml/min (calculated or measured)
Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) < 3 x ULN
Total bilirubin < 1.5 x ULN
Off calcineurin inhibitors for at least 2 weeks
Prednisone dose 20 mg/day
Patients with proliferative disease can be cytoreduced with cytotoxic chemotherapy at Investigator discretion, but there should be at least a 14 day window between start of cytoreductive therapy and start of daratumumab
Blast count 20K/day (hydrea use is allowed)

Exclusion Criteria

No demonstrable evidence of donor chimerism ( 55% donor CD3 or CD33 chimerism)
Patients with a molecular mutation without chromosomal abnormalities or declining chimerisms (MRD status must be verified by surface marker and mutational analyses)
Active graft-versus-host disease (GvHD) grades II-IV; prior acute GVHD could have occurred but resolved at time of initiation of daratumumab
Extensive chronic GvHD requiring ongoing immunosuppression with calcineurin inhibitors
Patients with FLT3+ AML or blast crisis CML who have not yet received post-transplant TKI therapy
Active central nervous system (CNS) disease testicular disease
EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination
(anti-HBs positivity as the only serologic marker) AND a known history of
prior HBV vaccination, do not need to be tested for HBV DNA by PCR
seropositive for hepatitis C (except in the setting of a sustained virologic
response [SVR], defined as aviremia at least 12 weeks after completion of
antiviral therapy)
Patients must not have moderate or severe persistent asthma within the past 2 years and must not have currently uncontrolled asthma of any classification
History of grade IV anaphylactic reaction to monoclonal antibody therapy
Active autoimmune disease prior to transplant
Concurrent use of any other investigational drugs
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note